Skip to main content

Phase 1b, Multicenter, Open-Label Study of Marizomib with Temozolomide and Radiotherapy in Patients with Newly Diagnosed WHO Grade IV Malignant Glioma. MRZ112

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Triphase Research and Development Corp

Start Date

December 1, 2016

End Date

March 31, 2020
 

Administered By

Duke Cancer Institute

Awarded By

Triphase Research and Development Corp

Start Date

December 1, 2016

End Date

March 31, 2020